Skip to main content
. Author manuscript; available in PMC: 2016 Jan 31.
Published in final edited form as: Cancer Res. 2015 Jan 14;75(3):594–604. doi: 10.1158/0008-5472.CAN-14-2362

Figure 7. Preclinical testing of CGI1746.

Figure 7

(A) Flow histograms of eFluxx dye retention assays using BTKOE ARP1 and OPM2 cells treated with CGI1746.

(B) Bar diagram of colony formation results indicating CGI1746-dependent reductions in clonogenicity of GFPHighBTKHigh vs. GFPLowBTKLow myeloma cells.

(C) Kaplan-Meier survival curve (left) of C57BL/KaLwRij mice treated with IV injections of either SP or non-SP 5TGM1 cells, followed by treatment of mice with CGI1746 or solvent control and the right panel is a graph of mean serum IgG2b levels of tumor-bearing mice.

(D) Column diagram presenting results of colony formation assays of hematopoietic stem cells (HSC) obtained from BTK-deficient Xid or normal mice.

(E) Working model on the putative mechanisms by which BTK promotes stemness and drug resistance in myeloma.